Current international risk stratification is based on the patient’s age, tumour site, tumour size, PAX-FOXO1 fusion status, presence of nodal involvement or metastatic disease and the Intergroup Rhabdomyosarcoma Studies (IRS) post-surgical group staging [14, 15, 35–37]. The gene discussed is FOXO1; the disease is neoplasm.